Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,186.74
(
-1.10%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 28
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: genisi post# 85722

Monday, 03/01/2010 1:58:41 PM

Monday, March 01, 2010 1:58:41 PM

Post# of 257580
End of the way for narlaprevir (SCH 900518), MK-7009 is the chosen one:

Merck had to choose among similar drugs in two research areas: hepatitis C and cancer. In December, Merck said its hepatitis C drug, MK-7009, also known as vaniprevir, would take priority over a similar drug from Schering.


http://www.nasdaq.com/aspx/stock-market-news-story.aspx?storyid=201003011141dowjonesdjonline000505&title=merck-touts-heart-infection-drugs-in-pipeline-update
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today